Introduction
============

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder (FGID) and is one of the most commonly diagnosed gastrointestinal diseases. The worldwide prevalence of IBS ranges from 10% to 20% \[[@gow047-B1],[@gow047-B2]\] with an estimated incidence of 1.4--1.5% according to long follow-up studies lasting 10--12 years \[[@gow047-B3], [@gow047-B4]\]. IBS is more common in women and in young adults \[[@gow047-B5]\]. IBS is responsible for about one-third of all referrals to gastroenterology specialists and is associated with significant economic costs and psychosocial burden \[[@gow047-B6]\].

The recent ROME IV Consensus requires abdominal pain to be recurrent and associated with defecation or change in bowel habits ([Table 1](#gow047-T1){ref-type="table"}) \[[@gow047-B9]\]. IBS subtypes include constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and IBS with predominant irregular (mixed diarrhea/constipation) bowel habits (IBS-M). IBS subtypes are classified according to the 7-point Bristol Stool Form Scale, which is based on stool appearance ranging from type 1 (separate hard lumps like nuts, hard to pass) to type 7 (watery, no solid pieces, entirely liquid) and is considered a reliable marker for colonic transit \[[@gow047-B9]\]. IBS subtyping is more accurate when patients have at least 4 days of abnormal bowel habits monthly in the absence of any specific treatment such as laxatives or antidiarrheal agents using a diary report of at least 14 days. An alteration in stool consistency (i.e. hard/lumpy stools or loose/watery stools) for more than 25% of bowel movements is the threshold for classification in the various IBS subtypes. Table 1.Diagnostic criteria for irritable bowel syndrome (IBS) \[**9**\]Recurrent abdominal pain (on average at least 1 day per week in the last 3 months) associated with two or more of the following criteriarelated to defecationassociated with a change in frequency of stoolassociated with a change in form (consistency) of stoolCriteria must be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis

A number of pathophysiological abnormalities have been described in IBS patients \[[@gow047-B13]\] and include visceral hypersensitivity \[[@gow047-B16]\], motor abnormalities of the gastrointestinal tract \[[@gow047-B20]\], infectious gastroenteritis \[[@gow047-B24]\], intestinal inflammation and visceral hyperalgesia \[[@gow047-B28],[@gow047-B29]\], genetic susceptibility \[[@gow047-B30],[@gow047-B31]\] and psychosocial factors \[[@gow047-B32]\].

The intestinal microbiota plays a key role in metabolic, protective and structural functions \[[@gow047-B15],[@gow047-B35]\] ([Figure 1](#gow047-F1){ref-type="fig"}). The role of altered intestinal microbiota in IBS has been progressively investigated \[[@gow047-B46]\] (see also ref. \[[@gow047-B15]\] for extensive information) and is shown to undergo either qualitative, quantitative and/or locoregional changes. Such changes might heavily affect the fermentation capacity in IBS compared with healthy subjects \[[@gow047-B15],[@gow047-B36],[@gow047-B46]\]. Major abnormalities involve temporal instability \[[@gow047-B51],[@gow047-B52]\], degree of variations \[[@gow047-B53],[@gow047-B54]\] and microbiota composition according to IBS subtypes \[[@gow047-B47],[@gow047-B52],[@gow047-B55]\] and increased intestinal mucosal permeability associated with a low-grade of inflammation \[[@gow047-B15],[@gow047-B51],[@gow047-B56]\]. Figure 1Complex pathways linking diet to microbiota to fermentation and a number of metabolic processes in the body. Fermented dietary fiber results in short-chain fatty acids (SCFAs) production. In enterocytes, this process provides an energy source and is associated with histone deacetylase (HDAC) inhibition in enterocytes, stimulation of intestinal gluconeogenesis and metabolic regulation. SCFAs stimulate the G-protein coupled receptor 41 and 43 while the secondary bile acid lithocholic acid (LCA) and deoxycholic acid (DCA) stimulate the bile acid receptor TGR5 in the enteroendocrine cell with release of glucagon-like peptide-1 (GLP-1). This step, in turn, increases incretin secretion, suppresses appetite and reduces intestinal transit. Following microbiota biotransformation of primary into secondary bile salts, the stimulation of TGR5 in the brown adipose tissue promotes thermogenesis and energy expenditure. Also, the deconjugation of taurobetamuricholic acid (tbMCA) provides the repression of the natural farnesoid X receptor (FXR), decreased bile acid synthesis and changes of fatty acid (FA) metabolism. Gram-negative bacterial membranes produce lipopolysaccharide (LPS) a pro-inflammatory molecule that induces macrophage recruitment and polarization in white adipose tissue inducing inflammation through Toll-like receptor 4 (TLR4)*Adapted from: Arora T and Bäckhed F. The gut microbiota and metabolic disease: current understanding and future perspectives. J Intern Med 2016;280:339--49* \[45\].

Since the symptoms that define IBS are not unique, organic diseases that can mimic IBS (i.e. inflammatory bowel disease, celiac disease, intolerance for carbohydrates such as fructose and lactose, neoplasia, microscopic colitis etc.) must be excluded. The initial diagnosis of patients suspected to have IBS must therefore include a careful history, physical exam and limited diagnostic testing to evaluate for alarm features \[[@gow047-B59]\] that might require further evaluation. Alarm features include unexplainable or consistent weight loss, unexplained iron- deficiency anemia, rectal bleeding (in the absence of documented bleeding hemorrhoids or anal fissures), symptoms present at night, family history of colorectal cancer, celiac disease or inflammatory bowel disease, unexplainable fever and onset of symptoms after the age of 50 years. Limited laboratory studies include blood count (to rule out anemia or elevated white blood cell count) and, in patients with diarrhea, C-reactive protein (CRP), fecal calprotectin \[[@gow047-B60]\], serology for celiac disease and stool analysis for parasites. Further diagnostic tests to be considered on a case-by-case basis include colonoscopy and upper endoscopy with biopsies and H2-breath tests to rule out carbohydrate malabsorption \[[@gow047-B36],[@gow047-B37],[@gow047-B61]\].

After establishing a confident diagnosis of IBS, a consistent and therapeutic relationship must be established with the patient. This approach has been shown to improve patient outcomes \[[@gow047-B62]\]. A patient's expectations must be clearly identified and, if possible, addressed \[[@gow047-B65]\]. Therapy is based on both type and severity of IBS symptoms.

The most common therapeutic approaches for IBS include education and reassurance, lifestyles (especially nutrition-based interventions), peripherally acting medications (which typically target motility) and centrally acting medications (which target visceral hypersensitivity and pain) and psychological interventions (which aim to reduce the effects of stress or symptom-specific anxiety) \[[@gow047-B9],[@gow047-B66]\] ([Figure 2](#gow047-F2){ref-type="fig"}). This paper will focus on available dietary interventions for IBS and will review the evidence for nutrition-based therapies. Figure 2General therapeutic approaches in irritable bowel syndrome (IBS) patients

Food Intolerance
================

Nutrition-based interventions are often recommended by primary care physicians and gastroenterologists, especially when patients report that their symptoms worsen after eating certain foods \[[@gow047-B67]\], a condition generally referred to as food "intolerance" \[[@gow047-B68]\]. Approximately 84% of patients report that their symptoms are triggered by at least one food item \[[@gow047-B68]\], and 62% report limiting their diet on their own without assistance from a gastroenterologist or nutritionist \[[@gow047-B69]\]. These food triggers do not reflect food allergies (as it would, for example, in celiac disease). A dietary interview is required to identify specific foods that may cause or aggravate IBS symptoms. Attention should be paid to the ingestion of wheat, dairy products, coffee, fruits, juices, vegetables, sweetened soft drinks and chewing gum.

Although the mechanisms of food intolerance in IBS remain unclear, there are currently three proposed pathways by which intolerance is hypothesized to develop: food hypersensitivity (immune-mediated); food chemicals (bioactive molecules) and luminal distension \[[@gow047-B71]\]. In the food hypersensitivity hypothesis, it is suggested that low-grade inflammation may occur in response to certain foods as a result of increased epithelial barrier permeability \[[@gow047-B72]\]. In the food chemicals hypothesis, attention is directed to salicylates, glutamates and amines, which may act directly on neural and mast cells \[[@gow047-B73]\]. This hypothesis has traditionally been tested through elimination diets and requires further research. Finally, luminal distension has been proposed as a mechanism for food intolerance in IBS in that certain molecules may increase water and gas volume, thereby causing bloating, pain and increased visceral hypersensitivity. The dietary factors discussed in this paper will each target at least one of these mechanisms.

Common Dietary Targets in Treating IBS
======================================

Fiber
-----

Fiber can act as a bulking agent to improve intestinal transit and decrease constipation in a subgroup of IBS patients. Thus, dietary recommendations for IBS patients often include fiber supplementation, especially with soluble (psyllium/ispaghula husk) rather than insoluble (bran) fibers \[[@gow047-B59],[@gow047-B74]\]. Psyllium/ispaghula should be started from low doses in order to avoid gas and abdominal bloating side-effects \[[@gow047-B75]\]. The optimal dose of fiber for IBS has not been established, but in general a target of 20--30 grams of total diet and supplementary fiber is reasonable. The evidence for fiber as a treatment for IBS is mixed. A systematic review based on 12 trials found no beneficial effect for bulking agents (either soluble fiber or insoluble fiber) over placebo for improving abdominal pain, global assessment or symptom scores \[[@gow047-B78]\]. Another meta-analysis on 12 trials found marginal improvement of symptoms with fiber (ispaghula husk) \[[@gow047-B79]\].

Gas-producing foods
-------------------

IBS patients may also benefit from excluding gas-producing foods derived from fermentable substrates known to exacerbate symptoms. Foods associated with an increase in intestinal gas and flatulence include alcohol, apricots, bagels, bananas, beans, Brussels sprouts, caffeine, carrots, celery, onions, pretzels, prunes, raisins and wheat germ \[[@gow047-B15],[@gow047-B36],[@gow047-B80]\].

FODMAPs
-------

The acronym FODMAPs indicates common dietary Fermentable Oligo-, Di-, and Monosaccharides And Polyols, which includes fructans, galacto-oligosaccharides (Oligosaccharides), lactose (Disaccharide), fructose (Monosaccharide) especially in excess of glucose, mannitol, sorbitol, maltilol and xylitol (Polyols). The FODMAP family is composed of short-chain carbohydrates, which are poorly absorbed in the intestine. FODMAPs are contained in a large number of foods and are posited to influence IBS symptoms and other functional gastrointestinal diseases \[[@gow047-B81]\] ([Figures 3--6](#gow047-F3 gow047-F4 gow047-F5 gow047-F6){ref-type="fig"}). Figure 3The fructans, galacto-oligosaccharides (FGO) and principal FGO lactose-containing foods Figure 4The disaccharide lactose and principal lactose-containing foods Figure 5The monosaccharide fructose and principal fructose-containing foods Figure 6Polyols and principal polyol-containing foods

FODMAPs behave as osmotically active molecules in the lumen of the small intestine and colon. The intestinal microbiota induces rapid fermentation of FODMAPs with production of hydrogen (H2) and methane. These gasses increase intraluminal tension and act on the intestinal wall causing symptoms such as abdominal bloating and pain \[[@gow047-B82]\]. Another consequence of increased FODMAP fermentation might include increases in intestinal permeability and (low-grade) inflammatory response \[[@gow047-B83]\]. In a randomized, controlled, single-blind crossover trial, 30 IBS patients who had not previously tried diets for their IBS reported improvement in overall gastrointestinal symptom scores compared with those on a standard Australian diet. While all IBS subtypes reported greater satisfaction with stool consistency, patients with IBS-D also reported improvement in their stool frequency \[[@gow047-B84]\]. A diet low in FODMAPs might therefore be worth trying in IBS patients \[[@gow047-B84],[@gow047-B85]\], although long-term efficacy and safety, particularly on colonic health and microbiome, require further studies \[[@gow047-B75]\].

Other FODMAP-containing foods
-----------------------------

In IBS patients, a diet low in fructose, fructans or a mixture of both improved symptoms \[[@gow047-B86]\]. Another study found that a "traditional IBS diet" (i.e regular meal pattern; avoidance of large meals and gas-producing foods such as beans, cabbage, onions and fat; reduced intake of insoluble fibers and caffeine) improved the symptoms of IBS after 4 weeks, similar to a low-FODMAP diet \[[@gow047-B87]\]. Overall, given the potential health benefits of many FODMAP-containing foods, less restrictive diets need to be considered; if a low FODMAP diet is pursued, patients should progressively reintroduce some FODMAP-containing foods, while maintaining the best healthy diet \[[@gow047-B36],[@gow047-B81],[@gow047-B88]\].

Lactose
-------

Either genetic or acquired intestinal lactase deficiency is commonly found \[[@gow047-B89]\], and exaggerated fermentation of malabsorbed lactose by the intestinal microbiota may trigger or exacerbate IBS symptoms \[[@gow047-B90]\]. Although the final diagnosis of lactose intolerance requires the simultaneous evaluation of gastrointestinal symptoms and H~2~ levels in expired air by breath-testing with 25g lactose) \[[@gow047-B15],[@gow047-B36],[@gow047-B37],[@gow047-B89],[@gow047-B90]\], a trial of a lactose-free diet might be indicated in patients who do not improve after exclusion of gas-producing foods. For those patients with proven lactase deficiency, a diet poor in lactose \[[@gow047-B91],[@gow047-B92]\] might be indicated. The use of oral lactases \[[@gow047-B61]\] before the ingestion of lactose-containing foods might also be useful for decreasing or even abolishing the symptoms.

Sucrose
-------

Sucrose malabsorption is a relatively rare condition. The estimated prevalence in individuals of European descent ranges from 1:500 to 1:2000 \[[@gow047-B93],[@gow047-B94]\]. The prevalence appears to higher in Alaskan Eskimos and native individuals from Greenland, where the prevalence has been reported to be as high as 10% \[[@gow047-B95]\]. Severe congenital sucrase-isomaltase deficiency (CSID) is due to a mutation in the sucrase-isomaltase gene that encodes sucrose-isomaltase, on chromosome 3q26. Severe CSID usually presents in early childhood; however, less severe forms may present in adulthood. The gold standard for diagnosis is the assessment of enzymatic activity from small intestinal biopsy. A positive H2-sucrose breath test or genetic testing can also support the diagnosis of sucrose malabsorption.

Fructose
--------

Some foods and drinks (honey, high-fructose corn syrup, apples, mangoes, some pears and cherries, sweetened drinks, etc.) are enriched in the FODMAP fructose. Similar to lactose intolerance, a form of fructose intolerance also exists, particularly in the presence of excess fructose in foods \[[@gow047-B96]\]. A careful dietary survey should be taken in these patients \[[@gow047-B81]\], and a final diagnosis should be made (e.g. by means of H2-fructose breath test) \[[@gow047-B36]\]. According to Choi *et al* \[[@gow047-B97]\], about one-third of patients with suspected IBS had fructose intolerance, and their symptoms improved on a fructose-restricted diet. By contrast, noncompliance was associated with persistent symptoms. Patients with fructose intolerance, however, tend to conscientiously avoid a number of potentially fermentable and generally healthy foods \[[@gow047-B36]\]. A thoughtful re-education program with periodic follow-up is therefore necessary.

Gluten
------

Although the role of gluten in non-celiac IBS patients remains controversial, dietary restriction of gluten might be effective for decreasing IBS symptoms in some patients. The effect is particularly evident in IBS-D patients who report no improvement of bloating and flatulence when avoiding gas-producing foods or after starting a low FODMAP diet. Mechanisms of the impact of gluten in these patients might involve gut dysfunction, especially in patients with a genetic predisposition for celiac disease who do not show evidence of fully evolved disease \[[@gow047-B98]\]. Additionally, the gut barrier might be impaired in IBS-D patients \[[@gow047-B58]\]. Symptom improvement was shown in a double-blind, randomized, placebo-controlled rechallenge trial in 34 IBS patients without celiac disease (i.e. HLA-DQ2 and HLA-DQ8 negative or normal duodenal biopsies) and whose IBS symptoms were controlled on a gluten-free diet. Patients were randomized to receive either a small amount of gluten in the form of 2 bread slices plus 1 muffin per day or to continue a gluten-free diet. After 6 weeks, patients who were randomized to receive gluten had worse symptomatic control for overall symptoms, pain, bloating, stool consistency and tiredness as compared with patients who were randomized to receive no added gluten \[[@gow047-B99]\]. In another randomized controlled 4-week trial, 45 IBS-D patients were stratified for a gluten-containing or gluten-free diet. Patients using gluten exhibited global worsening of daily bowel movements, higher small bowel (not colonic) permeability as measured by the lactulose:mannitol ratio, decreased histologically proven expression of mRNA encoding tight junction proteins in the small bowel and rectosigmoid mucosa and cytokine production. Changes were more evident in patients with HLA-DQ2/8-positive genotype \[[@gow047-B58]\]. Interestingly, in a placebo-controlled, crossover rechallenge study conducted in 2013, the addition of a gluten-free diet to IBS patients already on a low FODMAP diet did not give additional benefit \[[@gow047-B100]\].

Nutraceutical products
----------------------

Curcumin is a phytochemical and a natural member of the Zingiberaceae ginger family that is derived from the rhizome (turmeric) of the indian herb *Curcuma longa* \[[@gow047-B101]\] **(**[Figure 7](#gow047-F7){ref-type="fig"}**)**. Curcumin has been used for centuries in both Ayurvedic and traditional Chinese medicine, targeting abdominal pain and bloating as well as inflammatory diseases (e.g. biliary disorders, rheumatism, sinusitis, injuries, fever) \[[@gow047-B102]\]. Of note, curcumin displays an anti-inflammatory activity *in vitro*, \[[@gow047-B105]\] and reduces mucosal injuries in the animal model of colitis \[[@gow047-B106]\]. Potential mechanisms of curcumin include the modulation of I-kappa B kinase activity, driven by inhibition of nuclear factor-κB (NF-kB) and pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin 1β and 6) \[[@gow047-B113]\]. Several clinical studies also support a role for curcumin in both inflammatory bowel disorders and functional gastrointestinal diseases. In a randomized, double blind placebo-controlled study in patients with ulcerative colitis, curcumin (2 g/day) plus sulfasalazine or mesalamine for 6 months improved the Clinical Activity Index and the endoscopic score and prevented acute ulcerative colitis flares \[[@gow047-B117]\]. In a randomized controlled clinical trial, curcumin plus mesalazine induced remission in patients with mild-to-moderate ulcerative colitis \[[@gow047-B118]\]. In a small group of IBS patients \[[@gow047-B119]\], curcumin at 72 mg or 144 mg, given daily for 8 weeks, decreased abdominal pain intensity and improved quality of life. Figure 7Chemical formula of curcumin

Anethole, the major component of fennel oil seeds, is chemically similar to the neurotransmitter dopamine and has a relaxant effect on intestinal smooth muscle, isolated rat uterus \[[@gow047-B120]\] and guinea pig trachea rings \[[@gow047-B121]\]. In a pilot study on IBS patients, the fennel reduced crampiform abdominal pain, a mechanism likely mediated by the anethole-dependent relaxation of intestinal smooth muscle \[[@gow047-B122]\]. The combination of curcumin-fennel essential oil has been recently used by our group and has improved symptoms and quality of life in IBS patients \[[@gow047-B123]\]. Further studies are required with longer follow-up and in subtypes of IBS.

Conclusions
===========

The most recent guidelines on classification of IBS \[[@gow047-B9]\] confirm that the diagnosis of IBS and its clinical subtypes must rely on identifying typical symptoms and excluding alarm features that may suggest an organic disease. IBS is a heterogenous disorder with complex pathogenetic mechanisms contributing to the clinical features of IBS, which include abnormal intestinal motility and permeability, carbohydrate fermentation nutrient absorption, gas production and alterations in the intestinal microbiota. History-taking in IBS patients is important for ruling out the role of certain foods or other dietary components in the generation of symptoms.

The first-line approach to IBS includes dietary education while looking at foods responsible for the onset and worsening of symptoms. The avoidance, and progressive re-introduction of specific food components represents a subsequent step while evaluating the effects of gas-producing foods, lactose and fructose intolerance, other specific FODMAPs and gluten. The ultimate role of diet in different IBS subtypes needs further studies.
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